Blinatumomab: a novel tumor immunotherapeutic drug for acute lymphoblastic leukemiaWANG Ting, MA Ying, MA Yi-ming, LIN Bi-rong2521-2525
An application of IPD in new drug research and development based on the case of T companyBI Ye, LI Yun-fei, XING Hua2530-2534,2593
Vitality of pharmaceutical science and technology service platform:taking drug discovery service platform in Zhejiang province as an exampleSHI Hai-yan, DONG Zuo-jun, SHAN Wei-guang2535-2539
Regulatory development of narcotic drugs in China and extraterritorial revelationLIU Yong, WU Xiao-ming, GU Jian-qin2540-2543,2554
Non-clinical study and evaluation thinking of biosimilar products in China: reviewing the case of anti-CD20 monoclonal antibodyYU Shan-shan, HU Xiao-min, WANG Hai-xue, WANG Qing-li, YU Bing2544-2547
Progress in application of in vitro models in drug-induced liver injuryWU Yu, GENG Xing-chao, WANG Ju-feng, LI Bo2548-2554
Bioequivalence of isophane protamine recombinant human insulin and protamine zinc recombinant human insulin injection in Beagle dogs董艳, 曾勇, 高晶, 伊秀林, 慈小燕, 李薇, 魏滋鸿, 武卫党, 李亚卓2555-2559,2598
Research progress of oral insulin preparationsZHANG Yi-zhuo, ZHANG Jun-wei, YIN Dong-dong, WANG Xing-lin, SONG Yan-ning2560-2566,2571